WO2009117567A3 - Substituted fullerenes as mri contrast agents - Google Patents
Substituted fullerenes as mri contrast agents Download PDFInfo
- Publication number
- WO2009117567A3 WO2009117567A3 PCT/US2009/037653 US2009037653W WO2009117567A3 WO 2009117567 A3 WO2009117567 A3 WO 2009117567A3 US 2009037653 W US2009037653 W US 2009037653W WO 2009117567 A3 WO2009117567 A3 WO 2009117567A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted fullerenes
- substituted
- sample
- magnetic resonance
- contrast agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
Landscapes
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Engineering & Computer Science (AREA)
- Signal Processing (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- High Energy & Nuclear Physics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Abstract
A contrast agent for enhancing contrast in in vivo magnetic resonance imaging, comprising a water-soluble, non-zero spin isotope-enriched substituted fullerene having a fullerene core or heterofullerene core and at least one substituent group bonded to at least one carbon of the fullerene core. A method of magnetic resonance imaging a sample, comprising (i) administering to the sample a plurality of substituted fullerenes; and (ii) detecting magnetic resonance signals from the sample. In the method, some or all of the plurality of substituted fullerenes may be non-zero spin isotope-enriched, but need not be. In the method, some or all of the plurality of substituted fullerenes may be hyperpolarized, but need not be.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3811008P | 2008-03-20 | 2008-03-20 | |
US61/038,110 | 2008-03-20 | ||
US4900208P | 2008-04-30 | 2008-04-30 | |
US61/049,002 | 2008-04-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009117567A2 WO2009117567A2 (en) | 2009-09-24 |
WO2009117567A3 true WO2009117567A3 (en) | 2010-02-25 |
Family
ID=40996605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/037653 WO2009117567A2 (en) | 2008-03-20 | 2009-03-19 | Substituted fullerenes as mri contrast agents |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009117567A2 (en) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19808865A1 (en) * | 1998-03-03 | 1999-09-09 | Bayerl | Production of crosslinked structures of colloidal dimensions, e.g. hollow spheres or films, useful as lubricants, drug delivery systems, contrast agents, therapy vectors, chromatograhic media, magnetic data storage coatings, etc. |
US20030065206A1 (en) * | 2001-10-01 | 2003-04-03 | Bolskar Robert D. | Derivatization and solubilization of insoluble classes of fullerenes |
WO2005097807A2 (en) * | 2004-03-26 | 2005-10-20 | Luna Innovations Incorporated | Pegylation and hydroxylation of trimetallic nitride endohedral metallofullerenes |
WO2006009696A2 (en) * | 2004-06-16 | 2006-01-26 | Hematrope Pharmaceuticals Inc | Anticoagulant contrast media |
US20070025918A1 (en) * | 2005-07-28 | 2007-02-01 | General Electric Company | Magnetic resonance imaging (MRI) agents: water soluble carbon-13 enriched fullerene and carbon nanotubes for use with dynamic nuclear polarization |
WO2007070466A2 (en) * | 2005-12-10 | 2007-06-21 | The President And Fellows Of Harvard College | In situ hyperpolarization of imaging agents |
WO2007143558A1 (en) * | 2006-06-01 | 2007-12-13 | William Marsh Rice University | Targeted nanostructures for cellular imaging |
-
2009
- 2009-03-19 WO PCT/US2009/037653 patent/WO2009117567A2/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19808865A1 (en) * | 1998-03-03 | 1999-09-09 | Bayerl | Production of crosslinked structures of colloidal dimensions, e.g. hollow spheres or films, useful as lubricants, drug delivery systems, contrast agents, therapy vectors, chromatograhic media, magnetic data storage coatings, etc. |
US20030065206A1 (en) * | 2001-10-01 | 2003-04-03 | Bolskar Robert D. | Derivatization and solubilization of insoluble classes of fullerenes |
WO2005097807A2 (en) * | 2004-03-26 | 2005-10-20 | Luna Innovations Incorporated | Pegylation and hydroxylation of trimetallic nitride endohedral metallofullerenes |
WO2006009696A2 (en) * | 2004-06-16 | 2006-01-26 | Hematrope Pharmaceuticals Inc | Anticoagulant contrast media |
US20070025918A1 (en) * | 2005-07-28 | 2007-02-01 | General Electric Company | Magnetic resonance imaging (MRI) agents: water soluble carbon-13 enriched fullerene and carbon nanotubes for use with dynamic nuclear polarization |
WO2007070466A2 (en) * | 2005-12-10 | 2007-06-21 | The President And Fellows Of Harvard College | In situ hyperpolarization of imaging agents |
WO2007143558A1 (en) * | 2006-06-01 | 2007-12-13 | William Marsh Rice University | Targeted nanostructures for cellular imaging |
Non-Patent Citations (2)
Title |
---|
BALL G. E. ET AL.: "Structural reassignement of the Mono- and Bis-Addition Products from the Addition Reactions of N-(diphenylmethylene)glycinate Esters to [60]Fullerene under Bingel conditions", J. ORG. CHEM., vol. 70, no. 24, 16 September 2005 (2005-09-16), XP007910747 * |
MEIER M. ET AL.: "A 13C INADEQUATE and HF-GIAO Study of C60H2 and C60H6 Identification of Ring Currents in a 1,2-Dihydrofullerene", J. AM. CHEM. SOC., vol. 124, 10 July 2002 (2002-07-10), pages 8090 - 8094, XP007910752 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009117567A2 (en) | 2009-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006054903A3 (en) | Method of cardiac imaging with the use of hyperpolarized 13 c-pyruvate | |
Richard et al. | Noncovalent functionalization of carbon nanotubes with amphiphilic Gd3+ chelates: toward powerful T1 and T2 MRI contrast agents | |
WO2005072780A3 (en) | Cellular labeling for nuclear magnetic resonance techniques | |
WO2011014648A3 (en) | METHODS AND SYSTEM FOR DETECTING SOLUBLE AMYLOID-β | |
WO2008008075A3 (en) | Magnetic resonance imaging (mri) agents: water soluble carbon-13 enriched fullerene and carbon nanotubes for use with dynamic nuclear polarization | |
WO2010028013A3 (en) | In vivo biofilm infection diagnosis and treatment | |
WO2006116021A3 (en) | Mri technique based on electron spin resonance and endohedral contrast agent | |
WO2006120584A3 (en) | Magnetic resonance imaging with short echo times | |
WO2010056590A3 (en) | Conjugates of 19f mr imaging tracers for use in multi-chromic mri imaging | |
WO2009129537A3 (en) | Magnetic microstructures for magnetic resonance imaging | |
Al Faraj et al. | Preferential macrophage recruitment and polarization in LPS-induced animal model for COPD: noninvasive tracking using MRI | |
GB0022341D0 (en) | Method | |
EP2113781A3 (en) | Nuclear Magnetic Resonance apparatus | |
WO2008139480A3 (en) | Assessment of blood-brain barrier disruption | |
WO2009105659A3 (en) | Echo-decay-acceleration data acquisition method for gas identification using a low-field gradient | |
WO2007115115A3 (en) | Targeted mr imaging agents | |
WO2010142760A3 (en) | Sensor and magnetic field unit for use in a magnetic resonance tomography system or in a magnetic resonance spectroscopy system | |
WO2005024442A3 (en) | Nanoparticulate probe for in vivo monitoring of tissue oxygenation | |
WO2002023209A3 (en) | Mri method involving the use of a hyperpolarized contrast agent | |
WO2010107178A3 (en) | Magnetic resonance imaging contrast agent with paramagnetic-inositol phosphates complexes | |
WO2009069051A3 (en) | Non-spherical contrast agents for cest mri based on bulk magnetic susceptibility effect | |
WO2008087445A3 (en) | Magnetic resonance imaging | |
Fonchy et al. | A new gadolinium‐based contrast agent for magnetic resonance imaging of brain tumors: Kinetic study on a C6 rat glioma model | |
WO2009117567A3 (en) | Substituted fullerenes as mri contrast agents | |
WO2005115105A3 (en) | Self-immolative magnetic resonance imaging contrast agents sensitive to beta-glucuronidase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09721994 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 15/12/2010 AND 25/02/2011) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09721994 Country of ref document: EP Kind code of ref document: A2 |